Author:
Ślusarczyk Aleksander,Zapała Piotr,Zapała Łukasz,Radziszewski Piotr
Abstract
Abstract
Objectives
Although smoking is a well-recognized causative factor of urothelial bladder cancer and accounts for 50% of cases, less is known about the prognostic significance of smoking on non-muscle invasive bladder cancer (NMIBC) prognosis. This systematic review and meta-analysis aimed to evaluate the effect of smoking on the risk of NMIBC recurrence and progression.
Materials and methods
We systematically searched Medline, Web of Science and Scopus databases for original articles published before October 2021 regarding the effect of smoking on NMIBC recurrence and progression. Information about smoking status and the number of events or odds ratio or hazard ratio for event-free survival must have been reported to include the study in the analysis. Quality In Prognosis Studies tool was utilized for the risk of bias assessment.
Results
We selected 64 eligible studies, including 28 617 patients with NMIBC with available data on smoking status. In a meta-analysis of 28 studies with 7885 patients, we found that smokers (current/former) were at higher risk for recurrence (OR = 1.68; 95% CI 1.34–2.09; P < 0.0001) compared to never smokers. Subgroup analysis of 2967 patients revealed that current smokers were at a 1.24 higher risk of recurrence (OR = 1.24; 95% CI 1.02–1.50; P = 0.03) compared to former smokers. A meta-analysis of the hazard ratio revealed that smokers are at higher risk of recurrence (HR = 1.31; 95%CI 1.15–1.48; P < 0.0001) and progression (HR = 1.18; 95%CI 1.08–1.29; P < 0.001) compared to never smokers. Detrimental prognostic effect of smoking on progression, but not for recurrence risk was also noted in the subgroup analysis of high-risk patients (HR = 1.30; 95%CI 1.09–1.55; P = 0.004) and BCG-treated ones (HR = 1.15; 95%CI 1.06–1.25; P < 0.001).
Conclusion
In conclusion, patients with non-muscle invasive bladder cancer and a history of smoking have a worse prognosis regarding recurrence-free and progression-free survival compared to non-smokers.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference95 articles.
1. Abd Elwahab KM, Desky EAE, Eldery MS, Mohammad FF, Seleem MM, El-Babouly IM (2021) Apparent diffusion coefficient value can predict poor bacillus calmette-guérin responders in T1HG/NMIBC: prospective cohort study. Clin Genitourin Cancer 19(4):e248–e254
2. Abufaraj M, Shariat SF, Haitel A, Moschini M, Foerster B, Chłosta P et al (2017) Prognostic role of N-cadherin expression in patients with non–muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 35(5):264–271
3. Adamkiewicz M, Bryniarski P, Kowalik M, Burzyński B, Rajwa P, Paradysz A (2021) Lymphocyte-to-monocyte ratio is the independent prognostic marker of progression in patients undergoing BCG-immunotherapy for bladder cancer. Front Oncol 26(11):655000
4. Ahirwar D, Kesarwani P, Manchanda PK, Mandhani A, Mittal RD (2008) Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. Cancer Genet Cytogenet 184(1):1–8
5. Ajili F, Manai M, Darouiche A, Chebil M, Boubaker S (2012) Tumor multiplicity is an independent prognostic factor of non-muscle-invasive bladder cancer treated with bacillus calmette-guerin immunotherapy. Ultrastruct Pathol 36(5):320–324
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献